Acadian Asset Management
CUE icon

Acadian Asset Management’s Cue Biopharma CUE Stock Holding History

Acadian Asset Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-415
Closed -$23K – 1773
2024
Q1 		$23K Buy
+415
New +$29.3K ﹤0.01% 1472
2023
Q1 		– Sell
-1,239
Closed -$104K – 1782
2022
Q4 		$104K Sell
1,239
-869
-41% -$79.5K ﹤0.01% 1421
2022
Q3 		$139K Buy
+2,108
New +$181K ﹤0.01% 1288
2020
Q2 		– Sell
-1,002
Closed -$426K – 2246
2020
Q1 		$426K Buy
1,002
+706
+239% +$342K ﹤0.01% 1001
2019
Q4 		$141K Buy
+296
New +$93K ﹤0.01% 1372

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Acadian Asset Management's CUE Position: Q2 2024 in Review

Acadian Asset Management sold out of Cue Biopharma (CUE) in Q2 2024, closing a stake of 415 shares — an estimated $23K sold.

Acadian Asset Management first reported a position in CUE in Q4 2019 and held it in 5 quarters. The position peaked at $426K in Q1 2020. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2024.

  • Acadian Asset Management reported no remaining Cue Biopharma position as of Q2 2024 after selling out during the quarter.
  • Acadian Asset Management sold 415 Cue Biopharma shares in Q2 2024, an estimated $23K.
  • Acadian Asset Management first reported a position in Cue Biopharma in Q4 2019 and held it in 5 quarters.
  • Acadian Asset Management's Cue Biopharma position peaked at $426K in Q1 2020.
  • 75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2024.

Based on Acadian Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.